3-(2-氟-6-碘苯基)-5-甲基-1,2,4-恶二唑 | 925215-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(2-氟-6-碘苯基)-5-甲基-1,2,4-恶二唑
• 英文名称: 3-(2-fluoro-6-iodophenyl)-5-methyl-1,2,4-oxadiazole
• CAS: 925215-03-8
• 化学式: C₉H₆FIN₂O
• 分子量: 304.062
• InChiKey: VRLPQPOLPAVABP-UHFFFAOYSA-N

物化性质

• 沸点：
  350.6±52.0 °C(Predicted)
• 密度：
  1.825±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-氟-6-碘苯基)-5-甲基-1,2,4-恶二唑 在 palladium diacetate 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists

  摘要：

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

  DOI：

  10.1021/jm061094b
• 作为产物：
  描述：

  2-氟-6-碘苯甲腈 在 盐酸羟胺 、 sodium t-butanolate 作用下， 以 乙醇 为溶剂， 反应 6.25h， 生成 3-(2-氟-6-碘苯基)-5-甲基-1,2,4-恶二唑
  参考文献：
  名称：

  Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists

  摘要：

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

  DOI：

  10.1021/jm061094b